144 related articles for article (PubMed ID: 15711199)
1. Is biopsy-proven cellular rejection an important clinical consideration in heart transplantation?
Kirklin JK
Curr Opin Cardiol; 2005 Mar; 20(2):127-31. PubMed ID: 15711199
[TBL] [Abstract][Full Text] [Related]
2. Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction.
Tsamandas AC; Pham SM; Seaberg EC; Pappo O; Kormos RL; Kawai A; Griffith BP; Zeevi A; Duquesnoy R; Fung JJ; Starzl TE; Demetris AJ
J Heart Lung Transplant; 1997 Jul; 16(7):723-34. PubMed ID: 9257254
[TBL] [Abstract][Full Text] [Related]
3. Cardiac allograft rejection late after transplantation is a risk factor for graft coronary artery disease.
Brunner-La Rocca HP; Schneider J; Künzli A; Turina M; Kiowski W
Transplantation; 1998 Feb; 65(4):538-43. PubMed ID: 9500630
[TBL] [Abstract][Full Text] [Related]
4. Additive value of immunologic monitoring to histologic grading of heart allograft biopsy specimens: implications for therapy.
Fisher PE; Suciu-Foca N; Ho E; Michler RE; Rose EA; Mancini D
J Heart Lung Transplant; 1995; 14(6 Pt 1):1156-61. PubMed ID: 8719463
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression.
McNamara D; Di Salvo T; Mathier M; Keck S; Semigran M; Dec GW
J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506
[TBL] [Abstract][Full Text] [Related]
6. Prevention and treatment of severe hemodynamic compromise in pediatric heart transplant patients.
Costello JM; Pahl E
Paediatr Drugs; 2002; 4(11):705-15. PubMed ID: 12390042
[TBL] [Abstract][Full Text] [Related]
7. Impaired circulating dendritic cell reconstitution identifies rejecting recipients after clinical heart transplantation independent of rejection therapy.
Athanassopoulos P; Vaessen LM; Balk AH; Takkenberg JJ; Maat AP; Weimar W; Bogers AJ
Eur J Cardiothorac Surg; 2005 May; 27(5):783-9. PubMed ID: 15848314
[TBL] [Abstract][Full Text] [Related]
8. Biopsy-negative cardiac transplant rejection: etiology, diagnosis, and therapy.
Fishbein MC; Kobashigawa J
Curr Opin Cardiol; 2004 Mar; 19(2):166-9. PubMed ID: 15075746
[TBL] [Abstract][Full Text] [Related]
9. Cardiac allograft rejection.
Patel JK; Kittleson M; Kobashigawa JA
Surgeon; 2011 Jun; 9(3):160-7. PubMed ID: 21550522
[TBL] [Abstract][Full Text] [Related]
10. Intravenous pulse administration of cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients.
Itescu S; Burke E; Lietz K; John R; Mancini D; Michler R; Rose E; Oz M; Edwards N
Circulation; 2002 Mar; 105(10):1214-9. PubMed ID: 11889016
[TBL] [Abstract][Full Text] [Related]
11. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
Herzberg GZ; Rossi AF; Courtney M; Gelb BD
J Heart Lung Transplant; 1998 Dec; 17(12):1195-200. PubMed ID: 9883760
[TBL] [Abstract][Full Text] [Related]
12. The prognostic impact of immunosuppression and cellular rejection on cardiac allograft vasculopathy: time for a reappraisal.
Mehra MR; Ventura HO; Chambers RB; Ramireddy K; Smart FW; Stapleton DD
J Heart Lung Transplant; 1997 Jul; 16(7):743-51. PubMed ID: 9257256
[TBL] [Abstract][Full Text] [Related]
13. Immunosuppression, diagnosis, and treatment of cardiac allograft rejection.
Patel JK; Kobashigawa JA
Semin Thorac Cardiovasc Surg; 2004; 16(4):378-85. PubMed ID: 15635544
[TBL] [Abstract][Full Text] [Related]
14. Experimental and clinical allogeneic heart transplant rejection: correlations between histology and immune reactivity detected by cytokine messenger RNA.
Normann SJ; Peck AB; Staples ED; Salomon DR; Mills RM
J Heart Lung Transplant; 1996 Aug; 15(8):778-89. PubMed ID: 8878760
[TBL] [Abstract][Full Text] [Related]
15. Daily noninvasive rejection monitoring improves long-term survival in pediatric heart transplantation.
Hetzer R; Potapov EV; Müller J; Loebe M; Hummel M; Weng Y; Warnecke H; Lange PE
Ann Thorac Surg; 1998 Oct; 66(4):1343-9. PubMed ID: 9800831
[TBL] [Abstract][Full Text] [Related]
16. Effects of methotrexate on acute rejection and cardiac allograft vasculopathy in heart transplant recipients.
Costanzo MR; Koch DM; Fisher SG; Heroux AL; Kao WG; Johnson MR
J Heart Lung Transplant; 1997 Feb; 16(2):169-78. PubMed ID: 9059928
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study.
Ross HJ; Gullestad L; Pak J; Slauson S; Valantine HA; Hunt SA
J Heart Lung Transplant; 1997 Feb; 16(2):179-89. PubMed ID: 9059929
[TBL] [Abstract][Full Text] [Related]
19. Evolution of untreated mild rejection in heart transplant recipients.
Lloveras JJ; Escourrou G; Delisle MB; Fournial G; Cerene A; Bassanetti I; Durand D
J Heart Lung Transplant; 1992; 11(4 Pt 1):751-6. PubMed ID: 1498143
[TBL] [Abstract][Full Text] [Related]
20. Immunosuppression switch in pediatric heart transplant recipients: cyclosporine to FK 506.
Swenson JM; Fricker FJ; Armitage JM
J Am Coll Cardiol; 1995 Apr; 25(5):1183-8. PubMed ID: 7534779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
